Competition for targets, a tougher stance from regulators and uneven performance are likely to create an uneasy environment for healthcare special purpose acquisition companies in 2022, S&P Global reports. A total of 107 SPACs that listed parts of the healthcare industry as their intended target went public in 2021, according to S&P Global Market Intelligence data. Deal volume picked up in the last four months of the year, with 23 IPOs in November and December. That uptick in volume means more competition for healthcare companies that are mature enough to go public. Read more.
Healthcare SPACs Face Hurdles in 2022 as Competition, Regulation Increases
